18 results about "Thromboembolic disease" patented technology

A vacuum aspiration system may be used to treat thromboembolic disease, such as deep vein thrombosis or pulmonary embolism. The system includes a housing, and a fluid flow path extending through the housing. An aspiration catheter is in fluid communication with the flow path, and a connector is configured to place a source of aspiration in communication with the flow path. A hemostasis valve is provided in the housing. The housing may be configured to receive and releasably engage a thrombus engagement tool.

The present invention discloses a ternary nano self-assembly particle that responds to and regulates the microenvironment of arterial thrombosis and a preparation method thereof. The ternary nano self-assembly particle uses asymmetric zinc phthalocyanine as a template and is self-assembled with a natural small molecule compound containing a para-benzoquinone mother core and a flavonoid compound through hydrophobic interaction, π-π interaction, and electrostatic interaction. The self-assembly nanoparticles provided by the present invention can adsorb plasma proteins in situ in the circulation of the organism and form a protein corona of multiple plasma protein components on the surface; and it can respond to the shear force that increases sharply at the arterial thrombosis site to achieve passive targeting and fixed-point release; in addition, the self-assembly nanoparticles can regulate the arterial thrombosis microenvironment by inhibiting the NF-κB signaling pathway, inhibiting the formation of neutrophil extracellular traps, inhibiting glycolysis, and promoting the cGMP-mediated signaling pathway, thereby significantly improving the prognosis of carotid thrombotic diseases. It also has good biosafety and provides a new nano-therapeutic drug for arterial thrombosis.

The present invention relates to a solid pharmaceutical dosage form for oral administration, comprising (4S)-24-chloro-4-ethyl-73-fluoro-35-methoxy-32, 5-dioxo-14-(trifluoromethyl)-32H-6-aza-3 (4, 1)-pyridine-1 (1)-[1, 2, 3] triazole-2 (1, 2), 7 (1)-dibenzaheptaphane-74-carboxamide (active ingredient (I)), and a pharmaceutically acceptable salt thereof. The active ingredient (I) is present in amorphous form and is released immediately from a solid pharmaceutical dosage form for oral administration, and to a method for the production thereof, to the use thereof as a medicament, and to the use thereof for the treatment and / or prophylaxis of diseases, in particular diseases, such as diseases. Use in particular for cardiovascular disorders, preferably thrombotic or thromboembolic disorders and oedema and ocular disorders

The present invention covers the use of chymase inhibitors in general and more in particular substituted bicyclically substituted uracils of general formula (I) as described and defined herein, and 3-methylbenzo-[b]thiophene)-2-sulfonamido derivatives of general formula (II) for manufacturing pharmaceutical compositions for the treatment or prophylaxis of stroke, pulmonary embolism, deep or superficial vein thrombosis, thrombotic microangiopathy, thrombotic microangiopathy in hypercoagulable states after infection, inflammation, transplantation, disseminated intravascular coagulation, vaccine-induced immune thrombotic thrombocytopenia, vascular access site thrombosis or occlusion.

The present invention relates to a solid pharmaceutical dosage form for oral administration containing (4S)-2 4 -chloro-4-ethyl-7 3 -fluoro-3 5 -methoxy-3 2 ,5-dioxo-1 4 -(trifluoromethyl)-3 2 H-6-aza-3(4,1)-pyridina-1(1)-[1,2,3]triazola-2(1,2),7(1)-dibenzena-heptafane-7 4 -carboxamide (active ingredient (I)), characterized in that the active ingredient (I) is present in an amorphous form and is immediately released from the solid pharmaceutical dosage form for oral administration, a method for preparing the same, its use as a medicine, and its use for the treatment and / or prevention of diseases, particularly cardiovascular diseases, preferably thrombotic or thromboembolic diseases, and edema, and eye diseases. 【Chemical formula 1】 TIFF2026509613000011.tif37158

The application discloses a cinnoline PAR4 antagonist and medical application thereof. The application relates to a compound of formula (I), stereoisomers, tautomers, pharmaceutically acceptable salts, esters, solvates or prodrugs thereof. The compound of the application can inhibit and prevent platelet aggregation induced by PAR4, can be used for treating and preventing thromboembolic diseases, and thus can be used as an anti-platelet drug.

The invention belongs to the field of medicinal chemistry, and particularly relates to ligustrazine stilbene polyphenol aromatic acid ether compounds, pharmaceutically acceptable salts thereof, a preparation method thereof, a pharmaceutical composition and an application of the ligustrazine stilbene polyphenol aromatic acid ether compounds. The ligustrazine stilbene polyphenol aromatic acid ether compound and the pharmaceutically acceptable salt thereof have a remarkable anti-platelet aggregation effect, and can be used for preparing drugs for resisting platelet aggregation, preventing or treating cardiovascular diseases or treating or preventing thromboembolic diseases.

The present disclosure provides pharmaceutical compositions comprising an anticoagulant and pyruvic acid. Also provided are dosage forms comprising the pharmaceutical composition and methods for treating a thromboembolic disorder in a patient in need thereof, reducing the reoccurrence of a deep vein thrombosis or a pulmonary embolism in a patient in need thereof, preventing a venous thromboembolism (VTE) in an acutely ill patient, reducing the risk of a major cardiovascular event in a patient with coronary artery disease in a patient in need thereof, method for reducing the risk of a major thrombotic vascular event in a patient with peripheral artery disease (PAD), treating VTE or reducing the risk of reoccurrence of VTE in a pediatric patient in need thereof, thromboprophylaxis in a patient with congenital heart disease after a Fontan procedure, treating atherosclerosis, myocardial infarct, pulmonary embolism or deep venous thrombosis in a patient in need thereof, or preventing one or more thromboembolic or hemorrhagic events in a patient with atrial fibrillation by comprising administering the pharmaceutical composition or transdermal patch described herein to the patient.

The present invention covers the use of chymase inhibitors in general and more in particular substituted bicyclically substituted uracils of general formula (I) as described and defined herein, and 3-methylbenzo-[b]thiophene)-2-sulfonamido derivatives of general formula (II) for manufacturing pharmaceutical compositions for the treatment or prophylaxis of stroke, pulmonary embolism, deep or superficial vein thrombosis, thrombotic microangiopathy, thrombotic microangiopathy in hypercoagulable states after infection, inflammation, transplantation, disseminated intravascular coagulation, vaccine-induced immune thrombotic thrombocytopenia, vascular access site thrombosis or occlusion.

A vacuum aspiration system and methods of use are disclosed. The system and method can be configured to provide deep pulsatile suction to a catheter body to more efficiently aspirate a clot material from a patient. In some embodiments, a deep pulse can include a rapid increase in flow rate of the fluid through the catheter body to a sustained high flow rate range for a short period of time followed by a rapid decrease in the flow rate to a low or negligible flow rate level to minimize blood loss without any changes to the suction pressure being applied to the catheter.

The invention belongs to the technical field of biological medicine, and discloses application of an active substance in preparation of a VKOR inhibitor and / or a vitamin K antagonist and an anticoagulant drug. The invention provides application of an active substance shown in a formula (1) or pharmaceutically acceptable salt thereof in preparation of a vitamin K epoxide reductase inhibitor. The active substance has VKOR inhibitory activity, can prevent liver from synthesizing blood coagulation factors and activating anticoagulant factors by blocking reduction of oxidized vitamin K and inhibiting circulation of vitamin K, has potential anticoagulant activity, and has the advantages of mild anticoagulant effect, low probability of occurrence of adverse hemorrhage events, good anticoagulant effect, high safety and the like. The compound has a good application prospect in preparation of anticoagulants and / or medicines for treating thromboembolic diseases.

This invention belongs to the field of pharmaceutical technology and relates to platelet aggregation inhibitors, their preparation methods, and applications. This invention provides compounds of general formula I and their pharmaceutically usable salts, tautomers, and pharmaceutically usable solvates, wherein R1, R2, and n are as described in the claims and specification. This invention also provides intermediates for preparing compounds of general formula I and their pharmaceutically usable salts, tautomers, and pharmaceutically usable solvates. The compounds of general formula I of this invention, their pharmaceutically usable salts, tautomers, pharmaceutically usable solvates, or pharmaceutical compositions thereof have platelet-inhibiting activity and can be used to prepare platelet aggregation inhibitors, which can be used to treat thromboembolic diseases, especially cerebral infarction.

The present invention relates to a deuterated aminopyridine derivative of formula I, its optical isomers or mixtures thereof, its crystal forms, its salts, its hydrates or solvates. The present invention also relates to a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a deuterated aminopyridine derivative, its optical isomers or mixtures thereof, its crystal forms, its salts, its hydrates or solvates. The compound represented by general formula I of the present invention is a BTK inhibitor and is a prophylactic and / or therapeutic agent for BTK-related diseases, has low hepatotoxicity, and has good therapeutic effects on allergic diseases, autoimmune diseases, inflammatory diseases, thromboembolic diseases or cancers.

The present invention relates to a method for preventing and / or treating thromboembolic diseases, comprising the following step: administering a coagulation factor XI (FXI) binding protein to a subject in need thereof, which binding protein can comprise at least one immunoglobulin single variable domain capable of specifically binding to FXI, wherein the at least one immunoglobulin single variable domain may comprise CDR1, CDR2, and CDR3 in a VHH as shown in any one of SEQ ID NOs: 4, 10, and 14.

The present invention relates to a heterocyclic compound, a pharmaceutical composition comprising same, and a preparation method for the heterocyclic compound, and further relates to a use of the compound in the preparation of a drug for treating thromboembolic diseases.

A vacuum aspiration system and methods of use arc disclosed. The system and method can be configured to provide deep pulsatile suction to a catheter body to more efficiently aspirate a clot material from a patient. In some embodiments, a deep pulse can include a rapid increase in flow rate of the fluid through the catheter body to a sustained high flow rate range for a short period of time followed by a rapid decrease in the flow rate to a low or negligible flow rate level to minimize blood loss without any changes to the suction pressure being applied to the catheter.

The invention provides a pharmaceutical composition. The pharmaceutical composition is prepared from atorvastatin, valsartan, amlodipine, folic acid and pharmaceutically acceptable auxiliary materials. The pharmaceutical composition has the advantages that the pharmaceutical composition provided by the invention can be used for treating hypertension combined with hyperlipemia, and meanwhile, through the synergistic effect of multi-factor synchronous regulation, the pharmaceutical composition can reduce thrombosis and vascular embolism, so that the occurrence risks of myocardial infarction, cerebral infarction and peripheral artery embolism are reduced, and the pharmaceutical composition has a good treatment effect on hypertension combined with hyperlipemia. Therefore, the compound can be used for preventing thromboembolic diseases. Meanwhile, the compound form of the product can improve the taking compliance of patients.

Provided are a PCSK9 antibody and the use thereof. The PCSK9 antibody can be used in the preparation of drugs for reducing lipoprotein levels in blood and for preventing or treating cardiovascular diseases or disorders and thromboembolic diseases or disorders.